Zijian Li

Professor at Peking University Third Hospital, doctoral supervisor, Director of Beijing Key Laboratory of Cardiovascular Receptor Research, Deputy Secretary-General of Chinese Association of Pathophysiology, Vice Chairman of the Professional Committee on Receptor Signal Transduction of Chinese Association of Pathophysiology, Vice Chairman of the Professional Committee on Vascular Medicine of Chinese Association of Pathophysiology, Vice Chairman/Secretary-General of the Professional Committee on Cardiovascular and Cerebrovascular of Beijing Society of Pharmacology. Serves as editorial board member for journals such as Molecular Pharmacology and Cardiology Plus. Has led over 20 national-level projects including NSFC Major Research Plan Integration Project on Vascular Research (Chief Scientist), NSFC Key International Cooperation Project, NSFC Key Regional Cooperation Project, General Projects, National “973” Project, and sub-projects of “Major New Drug Development” National Science and Technology Major Project. Series of studies have published over 100 SCI papers in Cell subsidiary journals Trends in Cell Biology, Trends in Pharmacological Sciences, Eur Heart J, Cell Research, Pharmacology and Therapeutics, Cell Death and Differentiation, Acta Pharmaceutica Sinica B, etc. As first inventor, has been granted 9 national invention patents. Has received 4 first prizes for provincial and ministerial-level scientific and technological progress.

Research Direction: Cardiovascular Clinical Pharmacy/Cardiovascular Pharmacology

1. Kaihang Guan, Zijian Li*. β-adrenergic receptor inhibits heart regeneration by downregulating Yap m6A modification. Cell Death Dis. 2025,14;16(1):294.
2. Xuening Liu, Zijian Li*. The role and mechanism of epigenetics in anticancer drug-induced cardiotoxicity. Basic Res Cardiol. 2025;120(1):11-24.